Aurigene Pharmaceutical Services earlier this year unveiled a $100 million investment plan aimed at accelerating growth across its CRDMO offerings, spanning small molecules, peptides, nutraceuticals, and biologics.

As part of the first phase, the company has already deployed $40 million at its Genome Valley facility in Hyderabad, India. This site is designed to support cell line development, clinical development, and small-scale manufacturing of biologics for innovative biotech and pharmaceutical companies.

Aurigene has now outlined the next phase of investments, amounting to approximately $60 million. Of this, $20 million has been invested in establishing a state-of-the-art API and intermediates block at one of its US FDA-approved facilities in Telangana. The newly operational block is dedicated to innovator pharmaceutical companies and is equipped to safely handle hazardous reactions, setting a new benchmark in advanced API manufacturing.

In addition, the company is investing $10 million to set up a dedicated GMP suite for small molecule manufacturing at its Mirfield, UK facility. This expansion is intended to better serve European biotech and pharmaceutical clients.

Aurigene is also strengthening its capabilities in peptide research, development, and manufacturing through a comprehensive investment strategy. Capacity expansion at its pilot facility has been completed, and a new R&D lab is now fully operational. Work is ongoing to enhance large-scale GMP capabilities. The company’s peptide platform will incorporate advanced technologies such as microwave-assisted synthesis, solid-phase peptide synthesis (SPPS), and liquid-phase peptide synthesis (LPPS), enabling efficient handling of complex multi-mer peptide APIs, including linear, branched, and cyclic structures.

Details regarding planned investments in nutraceuticals and biologics services have not yet been disclosed.

Overall, these strategic investments underscore Aurigene’s commitment to delivering integrated, next-generation pharmaceutical development and manufacturing solutions, helping accelerate the journey of new therapies from lab to market.